Long-term sedation with remimazolam besylate versus propofol in critically ill patients during invasive mechanical ventilation: a study protocol for a multicenter randomized non-inferior trial

Background: Remimazolam besylate is a novel ultra-short-acting benzodiazepine that can potentially be a safe and effective sedative in intensive care units. This study aims to assess whether remimazolam besylate is not inferior to propofol in maintaining mild-to-moderate sedation in critically ill p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xiaobo, Tang, Yun, Du, Ruofei, Yu, Yuan, Xu, Jiqian, Zhang, Jiancheng, Liu, Hong, Zou, Xiaojing, Ren, Lehao, Yuan, Shiying, Shang, You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416620/
https://www.ncbi.nlm.nih.gov/pubmed/37576823
http://dx.doi.org/10.3389/fphar.2023.1139872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416620/
https://www.ncbi.nlm.nih.gov/pubmed/37576823
http://dx.doi.org/10.3389/fphar.2023.1139872

Ejemplares similares